ENLIVEN THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ENLIVEN THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $28.93M, a 2084.97% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $10.71M, a 4477.35% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $209.00K, a 79.18% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $1.32M, a 28.78% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $2.29M, a 36.79% decline from fiscal 2024.
- ENLIVEN THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $3.63M, a 664.42% increase from fiscal 2023.
- ENLIVEN THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $475.00K, a 93.09% increase from fiscal 2022.
- ENLIVEN THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $246.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $28.93M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $10.71M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $2.29M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $209.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $1.32M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $234.00K 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $3.63M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $1.00M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $1.86M 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $320.00K 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $475.00K 10-K · filed 2025-03-13 | |
| 2023-09-30 | $84.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $141.00K 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $140.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $246.00K 10-K · filed 2024-03-14 | |
| 2022-06-30 | $5.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $228.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $136.00K 8-K · filed 2023-06-23 | |
| 2021-09-30 | $145.00K 10-Q · filed 2021-11-09 | |
| 2021-03-31 | $472.00K 10-Q · filed 2022-10-25 | |
| 2020-09-30 | $207.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $218.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |